Eye Diseases Pharmaceutical Intermediate Lifitegrast Powder CAS 1025967-78-5

Eye Diseases Pharmaceutical Intermediate Lifitegrast CAS 1025967-78-5 Powder

Intro
Litakast binds to integrin lymphocyte Functional Association Antigen-1 (LFA-1), a cell surface protein found on the surface of white blood cells and blocks interactionofLFA-1 with its associated ligand intracellular adhesion molecule-1 (ICAM-1). ICAM-1 expression in corneal and conjunctival tissues in dry eye disease. The LFA-1/ICAM-1 interaction may promote the formation of an immune synapse, leading to T-cell activation and migration to the target tissue. In vitro studies have shown that human T-cell line lifitegrast may inhibit T-cell adhesion to ICAM-1 and may inhibit the secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of litakast in dry eye disease is unknown.

Xingtai Xinzhou Technology Co., LTD.

Xingtai Xinzhou Technology Co., Ltd. was established in 2022 with strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures. Effectively promote the joint venture and cooperation with the major enterprises, manufacturers, with the idea of industrial development to serve the society and the majority of users. We always adhere to the market demand as the orientation, constantly synthesizing new high-tech chemical products and medical intermediates, mainly exported to the United States, India, South Africa, Nigeria and other countries and regions, has a wealth of export experience, to ensure transportation safety, can let each customer as soon as possible to safely receive the goods.